Anthem Biosciences Limited (ANTHEM) — NSE Stock Analysis
Sector: Healthcare. Industry: Biotechnology.
Company Overview
Anthem Biosciences Limited is a biotechnology and pharmaceutical company specializing as a Contract Research, Development, and Manufacturing Organization (CRDMO). Founded in 2006 and headquartered in Bengaluru, India, the company serves as an integrated solutions provider across the pharmaceutical value chain—from drug discovery and early development to commercial-scale manufacturing. Its distinctive capability set includes expertise in both small molecule New Chemical Entities (NCEs) and New Biological Entities (NBEs), supporting a broad spectrum of clients ranging from emerging biotech startups to large multinational pharmaceutical firms. A key feature of Anthem Biosciences is its advanced focus on innovation and technology-driven processes. The company also manufactures complex, fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional supplements, and biosimilars. Anthem’s model positions it as a vital partner in the global pharma sector, facilitating outsourced research and manufacturing services that enable biopharma companies to accelerate product timelines and reduce development risks. The company’s high quality standards, regulatory compliance, and customer-centric approach further establish its prominence and reliability in the international life sciences and healthcare industries.
Valuation Snapshot
- Market cap: —
- P/E: —
- P/B: —
- ROE: —
Blanket Finance is not a SEBI-registered investment adviser or research analyst. This content is for educational and informational purposes only.